LifeMap Sciences, a Subsidiary of BioTime, Announces Partnership with Appistry

  LifeMap Sciences, a Subsidiary of BioTime, Announces Partnership with
  Appistry

 Agreement will integrate critical sources of genetic and disease information
  into Appistry’s next-generation sequencing (“NGS”) reports for clinicians

Business Wire

ALAMEDA, Calif. -- April 23, 2013

LifeMap Sciences, Inc., a subsidiary of BioTime, Inc. (NYSE MKT:BTX),
announced today a collaborative partnership and value-added reseller agreement
with Appistry, Inc., which provides big-data computing that supports
life-science and medical analytics at hospitals and medical research centers
and organizations. The intent of the partnership is to integrate LifeMap’s
GeneCards^® and MalaCards databases of human genes and diseases into the DNA
and RNA sequence analysis outputs and reports produced by Appistry’s
leading-edge Ayrris™ computing environment. Appistry will market reports that
include the GeneCards^® and MalaCards data to clinicians and researchers under
a revenue share arrangement with LifeMap, based on sales of such reports.

Current U.S. annual spending on genetic testing and molecular diagnostics
according to a UnitedHealthcare 2012 report
(http://www.unitedhealthgroup.com/~/media/UHG/PDF/2012/UNH-Working-Paper-7.ashx
) is at least $3-$4 billion annually. Today’s healthcare eco-system is
increasingly dependent on genetic testing and molecular diagnostics,
particularly as the advent of next-generation sequencing (NGS) technologies
have enabled a substantial reduction in the costs associated with gene
sequencing, enabling rapid sequencing of the DNA of individual patients. Labs
and hospitals cite analysis of NGS data as a primary bottleneck to leveraging
genetic information to better diagnose disease, assess treatment options, and
develop the targeted therapies that will enable personalized medicine, an
expanding field in which medical decisions, practices, and therapeutic
products are being tailored to the individual patient based on their own
genes.

Appistry’s Ayrris™ computing environment supports the rapid assembly of
complex, data-intensive analytics that run a customer’s choice of open-source,
commercial, and proprietary tools at scale without requiring specialized
expertise in high-performance computing or a complex software development
effort. Under the partnership, Appistry will deliver access to data from
LifeMap’s GeneCards^® and MalaCards databases within the pipeline results and
personalized medicine reports provided by its Ayrris™ life science solutions
and services. GeneCards^®, the human gene compendium, provides concise genomic
information on all known and predicted human genes, including gene-disease
associations, variants and single nucleotide polymorphisms, gene function and
other fields of interest. MalaCards, the human disease database, contains
information relating to a wide array of human diseases and the roles of genes
in disease processes. LifeMap Sciences holds the exclusive worldwide license
to market GeneCards^® and MalaCards from Yeda Research and Development Company
Ltd., the commercial arm of the Weizmann Institute of Science.

“One of the biggest limitations on using next-generation sequencing in
clinical settings is the ability to effectively translate raw sequence data
into medically meaningful results,” said Kevin Haar, CEO of Appistry. “To
realize the promise of personalized medicine, organizations need to scale
their bioinformatics pipelines to handle thousands of patient cases, while
also providing information physicians can act on. Our partnership with LifeMap
enables medical researchers to extend their analytic processes to deliver a
better understanding of the biological pathways and disease states associated
with genetic samples.”

“We expect LifeMap Sciences to be the leading source of gene and disease
information for clinicians and patients in the rapidly growing fields of
molecular diagnostics, prevention and personalized medicine,” saidDavid
Warshawsky, Ph.D., CEO of LifeMap. “The combination of GeneCards^® and
MalaCards comprehensive gene and disease related knowledge with the end-to-end
NGS analysis workflow offered by Appistry will greatly enhance the potential
for improved diagnosis, prevention, and treatment of devastating conditions.”

About Appistry

Appistry (www.appistry.com) orchestratessolutions to big data problems, and
since 2001, the company’s fabric technology has empowered organizations and
researchers to transform vast data into actionable intelligence. Appistry
weaves together high-performance computing and analytics to provide the
throughput and scale required for diverse applications—from discovering new
medical therapies to delivering overnight packages, gaining clarity from
financial transactions, or deciphering military satellite images. In 2012,
Appistry was selected by the Broad Institute as the exclusive distributor of
the GATK for use in for-profit settings.

About LifeMap Sciences, Inc.

LifeMap Sciences’ (www.lifemapsc.com) core technology and business is based on
its integrated database suite, the discovery platform for biomedical and stem
cell research. This platform includes GeneCards^®, the leading human gene
database; LifeMap Discovery™, the database of embryonic development, stem cell
research and regenerative medicine; and MalaCards, the human disease database.
According to Google Analytics, the sites have generated more than 2,000,000
unique visitors with more than 13,000,000 page views in the past 12 months.
LifeMap Sciences also markets PanDaTox, an innovative, recently developed,
searchable database that can aid in the discovery of new antibiotics and
biotechnologically beneficial products.

In addition to database offerings, LifeMap Sciences is BioTime’s principal
marketing subsidiary for research products, including PureStem™ human
progenitor cell lines, GMP human embryonic stem (hES) cell lines, ESpan™
growth media for progenitor cell lines, and cell differentiation media for
non-therapeutic uses, via its LifeMap BioReagents™ portal. LifeMap Sciences
utilizes its databases as part of its online marketing strategy to reach life
sciences researchers at biotech and pharmaceutical companies and at academic
institutions and research hospitals worldwide.

In a therapeutic discovery collaboration with BioTime, LifeMap’s scientists
utilize LifeMap’s proprietary platform, including LifeMap Discovery™, its stem
cell database along with the GeneCards^® and MalaCards integrated database
suite, to aid in the development of BioTime’s proprietary PureStem™ human
progenitor cell lines into products for the treatment of human diseases,
especially degenerative diseases that might be treatable with cell replacement
therapies. The LifeMap Discovery™ platform will be used to select the
progenitor cell lines that are most likely to be useful in developing
cell-based regenerative medicine therapies for a wide range of diseases.

About BioTime, Inc.

BioTime, headquartered in Alameda, California, is a biotechnology company
focused on regenerative medicine and blood plasma volume expanders. Its broad
platform of stem cell technologies is enhanced through subsidiaries focused on
specific fields of application. BioTime develops and markets research products
in the fields of stem cells and regenerative medicine, including a wide array
of proprietary PureStem™ cell lines, HyStem^® hydrogels, culture media, and
differentiation kits. BioTime is developing Renevia™ (formerly known as
HyStem^®-Rx), a biocompatible, implantable hyaluronan and collagen-based
matrix for cell delivery in human clinical applications. BioTime's therapeutic
product development strategy is pursued through subsidiaries that focus on
specific organ systems and related diseases for which there is a high unmet
medical need. BioTime's majority owned subsidiary Cell Cure Neurosciences Ltd.
is developing therapeutic products derived from stem cells for the treatment
of retinal and neural degenerative diseases. BioTime's subsidiary OrthoCyte
Corporation is developing therapeutic applications of stem cells to treat
orthopedic diseases and injuries. Another subsidiary, OncoCyte Corporation,
focuses on the diagnostic and therapeutic applications of stem cell technology
in cancer, including the diagnostic product PanC-Dx™ currently being developed
for the detection of cancer in blood samples. ReCyte Therapeutics, Inc. is
developing applications of BioTime's proprietary induced pluripotent stem cell
technology to reverse the developmental aging of human cells to treat
cardiovascular and blood cell diseases. BioTime's subsidiary LifeMap Sciences,
Inc. markets GeneCards^®, the leading human gene database, as part of an
integrated database suite that also includes the LifeMap Discovery™ database
of embryonic development, stem cell research and regenerative medicine, and
MalaCards, the human disease database. LifeMap Sciences also markets BioTime
research products and PanDaTox, an innovative, recently developed, searchable
database that can aid in the discovery of new antibiotics and
biotechnologically beneficial products. Asterias Biotherapeutics, Inc. is a
new subsidiary being used to acquire the stem cell assets of Geron
Corporation, including patents and other intellectual property, biological
materials, reagents and equipment for the development of new therapeutic
products for regenerative medicine. BioTime's lead product, Hextend^®, is a
blood plasma volume expander manufactured and distributed in the U.S. by
Hospira, Inc. and in South Korea by CJ CheilJedang Corporation under exclusive
licensing agreements. Additional information about BioTime can be found on the
web at www.biotimeinc.com.

About the Weizmann Institute of Science and GeneCards

The Weizmann Institute of Science in Rehovot, Israel, is one of the world's
top-ranking multidisciplinary research institutions. Noted for its
wide-ranging exploration of the natural and exact sciences, the Institute is
home to 2,700 scientists, postdoctoral fellows, Ph.D. and M.Sc. students, and
scientific, technical and administrative staff. In addition, visiting
scientists and their families – over 500 from 35 countries in 2010 are
regularly hosted at the Institute. The Institute was founded in 1934 following
a donation to Dr. Chaim Weizmann, a noted biochemist and biotechnologist, who
envisioned the establishment of a world-class scientific research center in
Israel, and later also became the first President of the State of Israel.
Weizmann Institute’s Feinberg Graduate School was established in 1958, where
about 1000 M.Sc. and Ph.D. students are enrolled in studies covering the
Institute’s 18 departments, which are grouped into five faculties:
Biochemistry, Biology, Chemistry, Physics, and Mathematics and Computer
Science. The Institute’s technology transfer arm, Yeda Research and
Development Co. was the first company of its kind in Israel, and is currently
one of the most successful worldwide. Institute research efforts include the
search for new ways of fighting disease and hunger, examining leading
questions in mathematics and computer science, probing the physics of matter
and the universe, creating novel materials and developing new strategies for
protecting the environment. Particular excellence in bioinformatics and
systems biology is manifested, among others, in the GeneCards project,
initiated in 1996, under the leadership of Prof. Doron Lancet of the Dept. of
Molecular Genetics, Head of the Crown Human Genome Center. A team of 10 led by
Marilyn Safran continuously innovates and keeps GeneCards as a world-top human
gene compendium, automatically mining and integrating 100 worldwide web
resources.

Forward-Looking Statements

Statements pertaining to future financial and/or operating results, future
growth in research, technology, clinical development, and potential
opportunities for BioTime and its subsidiaries, along with other statements
about the future expectations, beliefs, goals, plans, or prospects expressed
by management constitute forward-looking statements. Any statements that are
not historical fact (including, but not limited to statements that contain
words such as "will," "believes," "plans," "anticipates," "expects,"
"estimates") should also be considered to be forward-looking statements.
Forward-looking statements involve risks and uncertainties, including, without
limitation, risks inherent in the development and/or commercialization of
potential products, uncertainty in the results of clinical trials or
regulatory approvals, need and ability to obtain future capital, and
maintenance of intellectual property rights. Actual results may differ
materially from the results anticipated in these forward-looking statements
and as such should be evaluated together with the many uncertainties that
affect the business of BioTime and its subsidiaries, particularly those
mentioned in the cautionary statements found in BioTime's Securities and
Exchange Commission filings. BioTime disclaims any intent or obligation to
update these forward-looking statements.

To receive ongoing BioTime corporate communications, please click on the
following link to join our email alert list:
http://phx.corporate-ir.net/phoenix.zhtml?c=83805&p=irol-alerts

Contact:

BioTime, Inc.
Peter Garcia, 510-521-3390, ext 367
Chief Financial Officer
pgarcia@biotimemail.com
Judith Segall, 510-521-3390, ext 301
jsegall@biotimemail.com
or
LifeMap Sciences, Inc.
Kenneth Elsner, 781-826-7719
COO
ke@lifemapsc.com
 
Press spacebar to pause and continue. Press esc to stop.